• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Advances in glaucoma research continue


Paul Lichter, MD, for the Collaborative Initial Glaucoma Treatment Studyreported the results of an analysis of variables reflecting iOP controlassociated with visual field loss over 5 years. Four hundred twenty-sevenpatients who were followed for more than 6 years were analyzed. They hadbeen randomly assigned to medical therapy or a filtering procedure. Dr.Lichter reported that visual field loss was significantly associated witha larger maximum IOP, increased IOP variation, and a higher mean IOP. Dr.Lichter suggested that ophthalmologists focus on keep patient IOPs under18 mm Hg for as long as possible and avoid wide swings in IOP.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Lorraine Provencher, MD, presenting slides
Katherine Talcott, MD, presenting slides
Katherine Talcott, MD, presenting slides
© 2024 MJH Life Sciences

All rights reserved.